Loading…
Based on limited metadata available, the FDA issued a warning letter to goodimmuno.com on November 14, 2022, regarding drug products. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined from the metadata alone. The warning falls under FDA's drug product regulatory authority, though the specific issuing office is not identified in the available information. Additional details about the company's specific violations and remedial actions would require review of the complete warning letter.